Application 218228
- Type
- ANDA
- Sponsor
- CIPLA LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | SIPONIMOD | SIPONIMOD | TABLET;ORAL | 0.25MG | No | No |
| 002 | SIPONIMOD | SIPONIMOD | TABLET;ORAL | 1MG | No | No |
| 003 | SIPONIMOD | SIPONIMOD | TABLET;ORAL | 2MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| MAYZENT | SIPONIMOD | Novartis Pharmaceuticals Corporation | 44492772-5aed-4627-bd85-e8e89f308bb3 | 2026-06-30 | Warnings, Adverse reactions | SIPONIMOD |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 81322 | ORIG | 2025-02-24 |